NorthX Biologics and Demeetra have announced a strategic collaboration. The goal is to help biotech companies move from gene to GMP manufacturing faster and with less risk.

The partnership combines Demeetra’s CleanCut CHO platform and cell line development services with NorthX Biologics’ GMP manufacturing expertise. NorthX also provides process development, MCB banking, scale-up, and fill-finish services.

Together, the companies offer a more direct path from early development to clinical material. The approach reduces tech-transfer delays and avoids rebuilding cell lines. It also removes the need to re-qualify processes when moving to manufacturing.

The collaboration addresses common challenges in early biologics development. These include long timelines, technical bottlenecks, and costly delays.

For emerging biotech companies, even small delays can affect funding and valuation. The partners say their model helps reduce those risks.

“Partnering with Demeetra strengthens our ability to support biotech companies with a rapid and reliable path to GMP material,” said Janet Hoogstraate, CEO of NorthX Biologics. “Companies no longer need to choose between strong cell line development and proven GMP execution.”

Jack Crawford, CEO of Demeetra, said the collaboration allows cell lines to move directly into manufacturing. This avoids rebuilds and downstream licensing discussions.

The companies say the offering provides several benefits. These include royalty-free cell line development and a coordinated transition from CLD to GMP manufacturing. The model also reduces technical and regulatory risk. It can shorten timelines to IND and Phase I studies.